Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Elan

Executive Summary

By the year 2003, Elan is hoping to be a top 50 pharmaceutical company with $2 bil. in revenues and $20 bil. in market capital, Elan Pharmaceuticals CEO Paul Goddard, PhD, declared Jan. 13 at the H&Q conference in San Francisco. Goddard reported estimated revenues of approximately $650 mil. for 1998, with $250 mil. in estimated U.S. sales for the year. The company expects approval of its anti-convulsant therapy Zonegram in the second quarter of 1999, Goddard said. Zonegram (zonisamide) received an "approvable" letter from FDA in March 1998, but the company did not respond until recently when the Zonegram database was updated to include the Japanese experience. The company also filed a BLA for its cervical dystonia therapy Neurobloc (botulinum toxin type B) in December, and has two NDA filings for Ziconotide for chronic pain and Miguard migraine therapy planned for the first quarter of 1999
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS033471

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel